Anthony Keech

ISIS-4 - A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction.

Robert T. Collins, R Peto, Marcus Flather et al. · Ghent University Academic Bibliography (Ghent University) · 1995 · 1.1K citations

Medicine, Cardiology, Pharmacology +13

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 948 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P. Bonaca, Patrice Nault, Robert P. Giugliano et al. · Circulation · 2017 · 754 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 677 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 596 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16